Emergent BioSolutions Inc. (EBS) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Emergent BioSolutions Inc. (EBS) advanced +1.83% to $7.22, trading at 29% of its 52-week range ($4.36 – $14.06). Stretched risk/reward at 7x P/E (9% return on capital) under elevated 10-year interest-rate pressure.
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of +14.52% and +4.09%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
https://www.bloomberg.com/news/articles/2026-10-27/congo-ebola-cases-top-10-000-as-violence-hits-health-workers
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -28.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on EBS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for EBS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Emergent BioSolutions Inc. (EBS) ranks #306 by composite RQD confidence (53/100, grade D+) and #492 by equity capitalization ($370.2M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently leads its immediate peer cohort in composite quantitative strength at 53/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EBS
ACTIVE
Emergent BioSolutions Inc. | D+ | 53/100 | 7.0x | 56.1% | 8.9% | +1.83% | $370.2M | Benchmark Subject |
| RLMD Relmada Therapeutics Inc. | D | 44/100 | — | — | -35.0% | +2.69% | $366.9M | /rlmd-vs-ebs → |
| SPRY ARS Pharmaceuticals Inc. | E | 27/100 | — | — | -35.0% | +0.27% | $364.0M | /spry-vs-ebs → |
| CYPH Cypherpunk Technologies Inc. | D- | 40/100 | 71.3x | — | -23.3% | +2.16% | $356.7M | /cyph-vs-ebs → |
| GALT Galectin Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -0.56% | $355.8M | /galt-vs-ebs → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Emergent BioSolutions Inc. (EBS) reported GAAP revenue of $742.9M (-28.8% vs. FY2024 revenue of $1.04B , and -29.2% cumulative change since FY2023) , GAAP net income of $52.6M, operating cash flow of $170.6M, and free cash flow of $156.8M (+338.0% YoY). On the balance sheet, EBS closed FY2025 with $1.32B in total assets against $572.1M in total debt (Altman Z-Score: 1.41, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $742.9M | $52.6M | $170.6M | $156.8M | $1.32B | $572.1M |
| FY2024 (FY) | 2024-12-31 | $1.04B | -$190.6M | $58.7M | $35.8M | $1.39B | $663.7M |
| FY2023 (FY) | 2023-12-31 | $1.05B | -$760.5M | -$206.3M | -$206.3M | — | — |
As of 2026-11-01, Emergent BioSolutions Inc. (NYSE: EBS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $7.22 (+1.83% 1D, market cap $370.2M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, EBS ranks #306 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EBS carries a Roarable D+ (53/100 RQD), trailing P/E of 7.0x, gross margin of 56.1%, and ROIC of 8.9%. By comparison, RLMD (Relmada Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $366.9M) and SPRY (ARS Pharmaceuticals Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $364.0M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).
Per EBS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001367644), Emergent BioSolutions Inc. generated $742.9M in revenue (-28.8% YoY), $52.6M in net income, and $156.8M in free cash flow against $1.32B in total assets and $572.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
EBS last traded at $7.22 (+1.83% on volume of 682,401 shares), positioning the stock +11.59% above its 50-day simple moving average ($6.47) and -9.86% below its 200-day simple moving average ($8.01). Across its 52-week range of $4.36 to $14.06, EBS sits at the 29.5% percentile with a 14-day RSI of 53.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.32 to $8.12).
Why EBS Stock advanced +1.83% Today — RQD Quant Desk Flash. Stretched risk/reward at 7x P/E (9% return on capital) under elevated 10-year interest-rate pressure.